Company intelligence / Profile preview

Medivation

San Francisco, California, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Commercial

Overview

Medivation's lead product Xtandi (enzalutamide) was approved in 2012 for resistant prostate cancer and generated approximately $2.2 billion in net sales worldwide over the year prior to acquisition. The company also had two promising late-stage assets in development: talazoparib (a PARP inhibitor for breast cancer in phase 3 clinical trials) and pidiluzimab (being developed for lymphoma and other blood-related diseases).

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

enzalutamide

Commercial

Indications: Metastatic castration-resistant prostate cancer, Non-metastatic prostate cancer, Hormone-sensitive prostate cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Astellas Pharma Inc. (for Xtandi)

Beyond the preview

Go deeper on Medivation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medivation.

Explore the full profile